News - PGR positive - LARVOL VERI

LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov)

P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026

1 day ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

ER positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive

Keytruda (pembrolizumab) • Lenvima (lenvatinib) • letrozole

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)

P1, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

6 days ago

Trial completion date

BRCA1 mutation • HER-2 negative • PGR positive • BRCA mutation

cyclophosphamide • veliparib (ABT-888)

10d

PIKALO-2: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) (clinicaltrials.gov)

P3, N=193, Recruiting, Eli Lilly and Company

10 days ago

New P3 trial

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)

ER positive • PIK3CA mutation • PGR positive

Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane • tersolisib (LY4064809)

11d

Dexamethasone Suppresses Already Low Estrogen Receptor Levels in Meningiomas. (PubMed, Int J Mol Sci)

The difference in intra-tumoral estrogen concentration is proposed as a potential cause for lower ER in ICM. Replacement of Dex and more sensitive ER assays are needed to determine the role of hormones in the causation and treatment of ER+ ICM.

11 days ago

Review • Journal

ER (Estrogen receptor) • PGR (Progesterone receptor)

ER positive • PGR positive

dexamethasone

11d

ROTOR: Epidemiology and Treatment of HR+/HER2- Breast Cancer in England (clinicaltrials.gov)

P=N/A, N=218677, Completed, Novartis Pharmaceuticals

11 days ago

New trial

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

ER positive • HR positive • HER-2 negative • PGR positive

12d

BRIA-ABC: Combination Study of SV-BR-1-GM With Retifanlimab (clinicaltrials.gov)

P1/2, N=36, Completed, BriaCell Therapeutics Corporation | Enrolling by invitation --> Completed | Trial completion date: Nov 2028 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026

12 days ago

Trial completion • Trial completion date • Trial primary completion date

ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)

HER-2 positive • HER-2 negative • PGR positive

cyclophosphamide • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)

12d

CAPItrue: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (clinicaltrials.gov)

P3, N=258, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting

12 days ago

Enrollment closed

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CD4 (CD4 Molecule)

HER-2 negative • PGR positive

fulvestrant • Truqap (capivasertib)

12d

PI3K/Akt/mTOR pathway expression profiling reveals age- and subtype-specific molecular heterogeneity in the Nigerian breast cancer landscape. (PubMed, Front Oncol)

ER+ and ER+/PR+ tumors maintain DNA repair and apoptotic competence despite high proliferative signaling, HER2+ and TNBC subtypes display genomic instability and apoptotic evasion. Critically, the study identifies an evolving biological "engine, " transitioning from AKT/hTERT-driven growth in young patients to a MAPK/NF-κB-dominant inflammatory profile and genomic collapse in older cohorts, necessitating age-tailored precision oncology and targeted inhibitors.

12 days ago

Journal • BRCA Biomarker • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BCL2 (B-cell CLL/lymphoma 2) • TERT (Telomerase Reverse Transcriptase) • MDM2 (E3 ubiquitin protein ligase) • GATA3 (GATA binding protein 3)

HER-2 positive • ER positive • PGR positive

20d

Pangeia-2: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer. (clinicaltrials.gov)

P=N/A, N=70, Recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

20 days ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CDK4 (Cyclin-dependent kinase 4)

HER-2 negative • HER-2 mutation • PTEN mutation • PGR positive

21d

Sociodemographic Profile, Reproductive Factors and Presentation Pattern in Breast Cancer Patients from North India: A Hospital Based Study. (PubMed, J Pharm Bioallied Sci)

Breast cancer in North India affects women at younger age with advanced stage presentation. Awareness, early diagnosis and improving access to care are needed to reduce disease burden.

21 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)

HER-2 positive • PGR positive

23d

RADIOLA: Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (clinicaltrials.gov)

P2, N=65, Completed, SOLTI Breast Cancer Research Group | Recruiting --> Completed

23 days ago

Trial completion

HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)

BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • HER-2 negative + AR positive + ER positive

Lynparza (olaparib)

25d

Study of 68Ga-R10602 (clinicaltrials.gov)

P1, N=36, Recruiting, Radionetics Oncology | Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2026 --> Jul 2026

25 days ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4)

ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive